Stimuli-responsive polymeric systems for controlled protein and peptide delivery: Future implications for ocular delivery

Molecules

Volumn 21, Issue 8, 2016, Pages

  Mahlumba, Pakama ^a   Choonara, Yahya E ^a   Kumar, Pradeep ^a   Du Toit, Lisa C ^a   Pillay, Viness ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Bioavailability; In situ; Ocular barriers; Ocular delivery; Pre corneal elimination; Protein and peptide delivery; Stimuli responsive polymer

Indexed keywords

DELAYED RELEASE FORMULATION; DRUG CARRIER; PEPTIDE; POLYMER; PROTEIN;

BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; EYE DISEASES; HEAT; HUMAN; MAGNETIC FIELD; PH; PROCEDURES;

BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE DISEASES; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNETIC FIELDS; PEPTIDES; POLYMERS; PROTEINS;

EID: 84982756967     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21081002     Document Type: Review

References (103)

1. Pisal, D. S.; Kosloski, M. P.; Balu-Iyer, S. V. Delivery of Therapeutic Proteins. J. Pharm. Sci. 2010, 99, 2557-2575.
2. Ratnaparkhi, M. P.; Chaudhari, S. P.; Pandya, V. A. Peptides And Proteins In Pharmaceuticals. Int. Curr. Pharm. Res. 2011, 3, 1-9.
3. Koyamatsu, Y.; Hirano, T.; Kakizawa, Y.; Okano, F.; Takarada, T.; Maeda, M. pH-responsive release of proteins from biocompatible and biodegradable reverse polymer micelles. J. Control. Release 2014, 173, 89-95.
4. Antosova, Z.; Mackova, M.; Kral, V.; Macek, T. Therapeutic application of peptides and proteins: Parenteral forever? Trends Biotechnol. 2009, 27, 628-635.
5. Sharma, J. P. K.; Bansal, S.; Banik, A. Noninvasive routes of proteins and peptides drug delivery. Indian J. Pharm. Sci. 2011, 73, 367-375.
6. Yellepeddi, V. K.; Palakurthi, S. Recent Advances in Ocular Drug Delivery. Adv. Drug Deliv. 2016, 32, 67-82.
7. Meshram, S.; Thorat, S. Ocular in Situ Gels: Development, Evaluation and Advancements. Sch. Acad. J. Pharm. 2015, 4, 340-346.
8. Vellonen, K. S.; Malinen, M.; Mannermaa, E.; Subrizi, A.; Toropainen, E.; Lou, Y. R.; Kidron, H.; Yliperttula, M.; Urtti, A. A critical assessment of in vitro tissue models for ADME and drug delivery. J. Control. Release 2014, 190, 94-114.
9. Kaur, I. P.; Kakkar, S. Nanotherapy for posterior eye diseases. J. Control. Release 2014, 193, 100-112.
10. Gaudana, R.; Jwala, J.; Boddu, S. H. S.; Mitra, A. K. Recent perspectives in ocular drug delivery. Pharm. Res. 2009, 26, 1197-1216.
11. Yasin, M. N.; Svirskis, D.; Seyfoddin, A.; Rupenthal, I. D. Implants for drug delivery to the posterior segment of the eye: A focus on stimuli-responsive and tunable release systems. J. Control. Release 2014, 196, 208-221.
12. Kompella, U. B.; Amrite, A. C.; Pacha Ravi, R.; Durazo, S. A. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog. Retin. Eye Res. 2013, 36, 172-198.
13. Kim, Y. C.; Chiang, B.; Wu, X.; Prausnitz, M. R. Ocular delivery of macromolecules. J. Control. Release 2014, 190, 172-181.
14. Oak, M.; Mandke, R.; Singh, J. Smart polymers for peptide and protein parenteral sustained delivery. Drug Discov. Today Technol. 2012, 9, 131-140.
15. Roy, D.; Cambre, J. N.; Sumerlin, B. S. Future perspectives and recent advances in stimuli-responsive materials. Prog. Polym. Sci. 2010, 35, 278-301.
16. Ruel-Gariépy, E.; Leroux, J.-C. In situ-forming hydrogels-review of temperature-sensitive systems. Eur. J. Pharm. Biopharm. 2004, 58, 409-426.
17. Cohen, S.; Lobel, E.; Trevgoda, A.; Peled, Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J. Control. Release 1997, 44, 201-208.
18. Gratieri, T.; Gelfuso, G. M.; Rocha, E. M.; Sarmento, V. H.; de Freitas, O.; Lopez, R. F. V. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur. J. Pharm. Biopharm. 2010, 75, 186-193.
19. Qi, H.; Chen, W.; Huang, C.; Li, L.; Chen, C.; Li, W.; Wu, C. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int. J. Pharm. 2007, 337, 178-187.
20. Miyazaki, S.; Suzuki, S.; Kawasaki, N.; Endo, K.; Takahashi, A. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int. J. Pharm. 2001, 229, 29-36.
21. Brown, H. S.; Meltzer, G.; Merrill, R. C.; Fisher, M.; Ferré, C.; Place, V. A. Visual effects of pilocarpine in glaucoma comparative study of administration by eyedrops or by ocular therapeutic systems. Arch. Ophthalmol. 1976, 94, 1716-1719.
22. Zhang, X. Z.; Jo Lewis, P.; Chu, C. C. Fabrication and characterization of a smart drug delivery system: Microsphere in hydrogel. Biomaterials 2005, 26, 3299-3309.
23. Almeida, H.; Amaral, M. H.; Lobao, P.; Lobo, J. M. S. In situ gelling systems: A strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov. Today 2014, 19, 400-412.
24. Wu, C.; Qi, H.; Chen, W.; Huang, C.; Su, C.; Li, W.; Hou, S. Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi 2007, 127, 183-191.
25. Srividya, B.; Cardoza, R. M.; Amin, P. D. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J. Control. Release 2001, 73, 205-211.
26. Gan, L.; Gan, Y.; Zhu, C.; Zhang, X.; Zhu, J. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int. J. Pharm. 2009, 365, 143-149.
27. Kushwaha, S. K.; Saxena, P.; Rai, A. Stimuli sensitive hydrogels for ophthalmic drug delivery: A review. Int. J. Pharm. Investig. 2012, 2, 54-60.
28. Horvát, G.; Gyarmati, B.; Berkó, S.; Szabó-Révész, P.; Szilágyi, B. Á.; Szilágyi, A.; Soós, J.; Sandri, G.; Bonferoni, M. C.; Rossi, S.; et al. Thiolated poly (aspartic acid) as potential in situ gelling, ocular mucoadhesive drug delivery system. Eur. J. Pharm. Sci. 2015, 67, 1-11.
29. Ye, M.; Kim, S.; Park, K. Issues in long-term protein delivery using biodegradable microparticles. J. Control. Release 2010, 146, 241-260.
30. Al-tahami, K.; Singh, J. Smart Polymer Based Delivery Systems for Peptides and Proteins. Recent Pat. Drug Deliv. Formul. 2007, 1, 65-71.
31. Ducat, E.; Deprez, J.; Gillet, A.; Noël, A.; Evrard, B.; Peulen, O.; Piel, G. Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: Benefits over classical vesicles. Int. J. Pharm. 2011, 420, 319-332.
32. Kim, M. S.; Lee, D. S. Biodegradable and pH-sensitive polymersome with tuning permeable membrane for drug delivery carrier. Chem. Commun. 2010, 46, 4481-4483.
33. Chiu, H. C.; Lin, Y. W.; Huang, Y. F.; Chuang, C. K.; Chern, C. S. Polymer vesicles containing small vesicles within interior aqueous compartments and pH-responsive transmembrane channels. Angew. Chemie Int. Ed. 2008, 47, 1875-1878.
34. El-Sherbiny, I. M. Enhanced pH-responsive carrier system based on alginate and chemically modified carboxymethyl chitosan for oral delivery of protein drugs: Preparation and in-vitro assessment. Carbohydr. Polym. 2010, 80, 1125-1136.
35. Gong, R.; Li, C.; Zhu, S.; Zhang, Y.; Du, Y.; Jiang, J. A novel pH-sensitive hydrogel based on dual crosslinked alginate/N-α-glutaric acid chitosan for oral delivery of protein. Carbohydr. Polym. 2011, 85, 869-874.
36. Schmucker, C.; Loke, Y. K.; Ehlken, C.; Agostini, H. T.; Hansen, L. L.; Antes, G.; Lelgemann, M. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A safety review. Br. J. Ophthalmol. 2011, 95, 308-317.
37. Huth, U. S.; Schubert, R.; Peschka-Süss, R. Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J. Control. Release 2006, 110, 490-504.
38. Garbern, J. C.; Hoffman, A. S.; Stayton, P. S. Injectable pH- and temperature-responsive poly (Nisopropylacrylamideco-propylacrylic acid) copolymers for delivery of angiogenic growth factors. Biomacromolecules 2010, 11, 1833-1839.
39. Kang Derwent, J. J.; Mieler, W. F. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans. Am. Ophthalmol. Soc. 2008, 106, 204-206.
40. Kumar, S.; Haglund, B. O.; Himmelstein, K. J. In Situ-Forming Gels for Ophthalmic Drug Delivery. J. Ocul. Pharmacol. Ther. 1994, 10, 47-56.
41. Cao, Y.; Zhang, C.; Shen, W.; Cheng, Z.; Yu, L. L.; Ping, Q. Poly (N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J. Control. Release 2007, 120, 186-194.
42. Bawa, P.; Pillay, V.; Choonara, Y. E.; du Toit, L. C. Stimuli-responsive polymers and their applications in drug delivery. Biomed. Mater. 2009, 4, 1-15.
43. Ward, M. A.; Georgiou, T. K. Thermoresponsive polymers for biomedical applications. Polymers 2011, 3, 1215-1242.
44. Hoffman, A. S. Hydrogels for biomedical applications. Adv. Drug Deliv. Rev. 2002, 54, 3-12.
45. Ninawe, P. R.; Hatziavramidis, D.; Parulekar, S. J. Delivery of drug macromolecules from thermally responsive gel implants to the posterior eye. Chem. Eng. Sci. 2010, 65, 5170-5177.
46. Thornton, P. D.; Mart, R. J.; Webb, S. J.; Ulijn, R. V. Enzyme-responsive hydrogel particles for the controlled release of proteins: designing peptide actuators to match payload. Soft Matter 2008, 4, 821.
47. Aimetti, A. A.; Tibbitt, M. W.; Anseth, K. S. Human Neutrophil Elastase Responsive Delivery from Poly (ethylene glycol) Hydrogels. Biomacromolecules 2009, 10, 1484-1489.
48. Itoh, Y.; Matsusaki, M.; Kida, T.; Akashi, M. Enzyme-responsive release of encapsulated proteins from biodegradable hollow capsules. Biomacromolecules 2006, 7, 2715-2718.
49. Yagai, S.; Kitamura, A. Recent advances in photoresponsive supramolecular self-assemblies. Chem. Soc. Rev. 2008, 37, 1520-1529.
50. Shum, P.; Kim, J. M.; Thompson, D. H. Phototriggering of liposomal drug delivery systems. Adv. Drug Deliv. Rev. 2001, 53, 273-284.
51. Peng, K.; Tomatsu, I.; Kros, A. Light controlled protein release from a supramolecular hydrogel. Chem. Commun. 2010, 46, 4094-4096.
52. Huang, Y. F.; Sefah, K.; Bamrungsap, S.; Chang, H. T.; Tan, W. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir 2008, 24, 11860-11865.
53. Kang, H.; Trondoli, A. C.; Zhu, G.; Chen, Y.; Chang, Y. J.; Liu, H.; Huang, Y. F.; Zhang, X.; Tan, W. Near-infrared light-responsive core-shell nanogels for targeted drug delivery. ACS Nano 2011, 5, 5094-5099.
54. Jin, Q.; Cai, T.; Wang, Y.; Wang, H.; Ji, J. Light-Responsive Polyion Complex Micelles with Switchable Surface Charge for Efficient Protein Delivery. ACS Macro Lett. 2014, 3, 679-683.
55. Zhao, H.; Sterner, E. S.; Coughlin, E. B.; Theato, P. O-Nitrobenzyl alcohol derivatives: Opportunities in polymer and materials science. Macromolecules 2012, 45, 1723-1736.
56. Mulvagh, S. L.; DeMaria, A. N.; Feinstein, S. B.; Burns, P. N.; Kaul, S.; Miller, J. G.; Monaghan, M.; Porter, T. R.; Shaw, L. J.; Villanueva, F. S. Contrast echocardiography: current and future applications. J. Am. Soc. Echocardiogr. 2000, 13, 331-342.
57. Zhao, Y.-Z.; Du, L.-N.; Lu, C.-T.; Jin, Y.-G.; Ge, S.-P. Potential and problems in ultrasound-responsive drug delivery systems. Int. J. Nanomedicine 2013, 8, 1621-1633.
58. Wang, J.; Pelletier, M.; Zhang, H.; Xia, H.; Zhao, Y. High-frequency ultrasound-responsive block copolymer micelle. Langmuir 2009, 25, 13201-13205.
59. Suslick, K. S. Sonochemistry. Science 1990, 247, 1439.
60. Casolaro, M.; Casolaro, I.; Bottari, S.; Del Bello, B.; Maellaro, E.; Demadis, K. D. Long-term doxorubicin release from multiple stimuli-responsive hydrogels based on α-amino-acid residues. Eur. J. Pharm. Biopharm. 2014, 88, 424-433.
61. Yin, R.; Wang, K.; Du, S.; Chen, L.; Nie, J.; Zhang, W. Design of genipin-crosslinked microgels from concanavalin A and glucosyloxyethyl acrylated chitosan for glucose-responsive insulin delivery. Carbohydr. Polym. 2014, 103, 369-376.
62. Zakharchenko, S.; Puretskiy, N.; Stoychev, G.; Stamm, M.; Ionov, L. Temperature controlled encapsulation and release using partially biodegradable thermo-magneto-sensitive self-rolling tubes. Soft Matter 2010, 6, 2633-2636.
63. Scott, I. U.; Karp, C. L.; Nuovo, G. J. Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia. Ophthalmology 2002, 109, 542-547.
64. Nemet, A. Y.; Sharma, V.; Benger, R. Interferon α2b treatment for residual ocular surface squamous neoplasia unresponsive to excision, cryotherapy and mitomycin-C. Clin. Exp. Ophthalmol. 2006, 34, 375-377.
65. Nakamura, M.; Kawahara, M.; Nakata, K.; Nishida, T. Restoration of corneal epithelial barrier function and wound healing by substance P and IGF-1 in rats with capsaicin-induced neurotrophic keratopathy. Investig. Ophthalmol. Vis. Sci. 2003, 44, 2937-2940.
66. Nishida, T. The role of fibronectin in corneal wound healing explored by a physician-scientist. Jpn. J. Ophthalmol. 2012, 56, 417-431.
67. Cameron, J. D.; Skubitz, A. P.; Furcht, L. T. Type IV collagen and corneal epithelial adhesion and migration. Effects of type IV collagen fragments and synthetic peptides on rabbit corneal epithelial cell adhesion and migration in vitro. Invest. Ophthalmol. Vis. Sci. 1991, 32, 2766-2773.
68. Kymionis, G. D.; Bouzoukis, D. I.; Diakonis, V. F.; Siganos, C. Treatment of chronic dry eye: Focus on cyclosporine. Clin. Ophthalmol. 2008, 2, 829-836.
69. Kunert, K. S.; Tisdale, A. S.; Gipson, I. K. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002, 120, 330-337.
70. Matsuda, S.; Koyasu, S. Mechanisms of action of cyclosporine. Immunopharmacology 2000, 47, 119-125.
71. Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Ezzat, M. K.; Singh, R. J. Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). Ophthalmology 2007, 114, 2179-2182.
72. Agrahari, V.; Agrahari, V.; Hung, W.-T.; Christenson, L.; Mitra, A. K. Composite Nanoformulation Therapeutics for Long Term Ocular Delivery of Macromolecules. Mol. Pharm. 2016.
73. Kingsley, R. E.; Marfurt, C. F. Topical substance P and corneal epithelial wound closure in the rabbit. Invest. Ophthalmol. Vis. Sci. 1997, 38, 388-395.
74. Nelson, J. D.; Gordon, J. F. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group. Am. J. Ophthalmol. 1992, 114, 441-447.
75. McCulley, J. P.; Horowitz, B.; Husseini, Z. M.; Horowitz, M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group. Trans. Am. Ophthalmol. Soc. 1993, 91, 367-390.
76. Finger, P. T.; Sedeek, R. W.; Chin, K. J. Topical Interferon Alfa in the Treatment of Conjunctival Melanoma and Primary Acquired Melanosis Complex. Am. J. Ophthalmol. 2008, 145, 124-129.
77. Jarrett, S. G.; Boulton, M. E. Consequences of oxidative stress in age-related macular degeneration. Mol. Aspects Med. 2012, 33, 399-417.
78. Gantyala, S. P.; Shekhar, H.; Vanathi, M.; Sinha, R.; Titiyal, J. S. Interferons in Ophthalmology Current Status and Advancing Trends. Delhi J. Ophthalmol. 2013, 23, 295-297.
79. Huerva, V.; Mangues, I. Treatment of conjunctival squamous neoplasias with interferon alpha 2ab. J. Fr. Ophtalmol. 2008, 31, 317-325.
80. Shen, J.; Deng, Y.; Jin, X.; Ping, Q.; Su, Z.; Li, L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int. J. Pharm. 2010, 402, 248-253.
81. Rauck, B. M.; Friberg, T. R.; Medina Mendez, C. A.; Park, D.; Shah, V.; Bilonick, R. A.; Wang, Y. Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo. Investig. Ophthalmol. Vis. Sci. 2013, 55, 469-470.
82. Yin, R.; Tong, Z.; Yang, D.; Nie, J. Glucose-responsive insulin delivery microhydrogels from methacrylated dextran/concanavalin A: preparation and in vitro release study. Carbohydr. Polym. 2012, 89, 117-123.
83. Velez-montoya, R.; Oliver, S. C. N.; Olson, J. L.; Fine, S. L.; Mandava, N.; Quiroz-mercado, H. Age-Related Macular Degeneration: Today's and Future Treatments. J. Ret. Vit. Dis. 2013, 33, 1487-1502.
84. Kute, R. B.; Gondkar, P. R.; Saudagar, S. B. Ophthalmic In-situ Gel: An Overview. World J. Pharm. Pharm. Sci. 2015, 4, 549-568.
85. Sieg, J. W.; Robinson, J. R. Mechanistic studies on transcorneal permeation of fluorometholone. J. Pharm. Sci. 1981, 70, 1026-1029.
86. Zarbin, M. A.; Rosenfeld, P. J. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010, 30, 1350-1367.
87. Athanasakis, K.; Fragoulakis, V.; Tsiantou, V.; Masaoutis, P.; Maniadakis, N.; Kyriopoulos, J. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. Clin. Ther. 2012, 34, 446-456.
88. Peng, R.; Qin, G.; Li, X.; Lv, H.; Qian, Z.; Yu, L. The PEG-PCL-PEG Hydrogel as an Implanted Ophthalmic Delivery System after Glaucoma Filtration Surgery; a Pilot Study. Med. hypothesis, Discov. Innov. Ophthalmol. 2014, 3, 3-8.
89. Liu, Z.; Li, J.; Nie, S.; Liu, H.; Ding, P.; Pan, W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int. J. Pharm. 2006, 315, 12-17.
90. Shastri, D.; Patel, L.; Parikh, R. Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery. J. Young Pharm. 2010, 2, 116-120.
91. Maurice, D. M.; Mishima, S. Ocular Pharmacokinetics; Springer: Berlin & Heidelberg, Germany, 1984; pp. 19-116.
92. Kuno, N.; Fujii, S. Recent Advances in Ocular Drug Delivery Systems. Polymers 2011, 3, 193-221.
93. Schoenwald, R. Textbook of Ocular Pharmacology; Lippincott-Raven: Philadelphia, PA, USA, 1997; pp. 119-138.
94. Xie, B.; Jin, L.; Luo, Z.; Yu, J.; Shi, S.; Zhang, Z.; Shen, M.; Chen, H.; Li, X.; Song, Z. An injectable thermosensitive polymeric hydrogel for sustained release of Avastin1 to treat posterior segment disease. Int. J. Pharm. 2015, 490, 375-383.
95. Du Toit, L. C.; Carmichael, T.; Govender, T.; Kumar, P.; Choonara, Y. E.; Pillay, V. In vitro, in vivo, and in silico evaluation of the bioresponsive behavior of an intelligent intraocular implant. Pharm. Res. 2014, 31, 607-634.
96. Li, P.; Shih, J.; Lo, R.; Saati, S.; Agrawal, R.; Humayun, M. S.; Tai, Y.; Meng, E. An electrochemical intraocular drug delivery device. Sens. Actuators 2008, 143, 41-48.
97. Lo, R.; Li, P.; Saati, S.; Agrawal, R.; Humayun, S.; Meng, E. A refillable microfabricated drug delivery device for treatment of ocular diseases. Lab Chip 2008, 8, 1027-1030.
98. Haghjou, N.; Soheilian, M.; Abdekhodaie, M. J. Sustained release intraocular drug delivery devices for treatment of uveitis. J. Ophthalmic Vis. Res. 2011, 6, 317-319.
99. Parlato, M.; Johnson, A.; Hudalla, G. A.; Murphy, W. L. Adaptable poly (ethylene glycol) microspheres capable of mixed-mode degradation. Acta Biomater. 2013, 9, 9270-9280.
100. Oubraham, H.; Cohen, S. Y.; Samimi, S.; Marotte, D.; Bouzaher, I.; Bonicel, P.; Fajnkuchen, F.; Tadayoni, R. Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011, 31, 26-30.
101. Prasad, P. S.; Schwartz, S. D.; Hubschman, J.-P. Age-related macular degeneration: Current and novel therapies. Maturitas 2010, 66, 46-50.
102. Juzenas, P.; Juzeniene, A.; Kaalhus, O.; Iani, V.; Moan, J. Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo. Photochem. Photobiol. Sci. 2002, 1, 745-748.
103. Malec, J.; Dot, D.; Cejková, J.; Br, B. Decreased expression of antioxidant enzymes in the conjunctival epithelium of dry eye (Sjögren's syndrome) and its possible contribution to the development of ocular surface oxidative injuries. Histol. Histopathol. 2008, 23, 1477-1483.